Phase III randomised trial comparing 6 vs. 12month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer final results of the JFMC370801 study

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study

16:19 EST 5 Mar 2019 | Nature Publishing

More From BioPortfolio on "Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study"